Home - Australian Pharmacist

Pharmacist recognised for contribution to pain management

Ruth Cooper - 2 May 2019

Industry

Pharmacists who have an interest in a specific field are in charge of their own development, says pain expert Joyce McSwan, who was recently...

Choosing wisely to achieve medicine safety

Ruth Cooper - 5 June 2019

Industry

The quality use of medicines is vital to ensure a sustainable healthcare system and better health outcomes for consumers. This was the dominant theme at...

How to advocate for your practice

Brian Bigg - 25 April 2022

Industry

Whether pitching collaboration ideas, PHN tenders or talking to politicians, all pharmacists must master the art of advocating for their own practice.

It’s time to use pharmacists’ skills properly

Dr Stephen Duckett - 11 July 2019

Industry

Australia’s pharmacists are underutilised. How can tapping pharmacists’ skills as medicines experts produce better healthcare outcomes? Pharmacists are highly trained, have deep expertise in medicines,...

Pharmacists vital leaders in Australian community during COVID-19 crisis

Dr Chris Freeman FPS - 14 April 2020

Industry

After a summer of bushfires, the outbreak of a novel coronavirus in China (later named COVID-19) was reported in January.

A voice for Australia and New Zealand at IPSF 2025

Aaliah Nelson - 9 September 2025

People

Australia and New Zealand had a voice at the IPSF World Congress, influencing discussions on education, practice and global health.

1...283284285...331 Page 284 of 331

1989	Establishment of the SAS The SAS was established as part of the Therapeutic Goods Act to maintain access to essential medicines not listed on the ARTG, while maintaining public safety.1
2016	Legalisation of medicinal cannabis Decades of restricted research and patent difficulties reduced the commercial incentive to fund the large clinical trials needed for full TGA registration. The SAS has become the default pathway for medicinal cannabis submissions10 – particularly for chronic pain and anxiety – increasing almost 100-fold since 2018.11
2017	Introduction of SAS-C New access pathway introduced in response to TGA medical devices review.3
2021	Discontinuation of opioids used in palliative care SAS volumes increased between 2021 and 2023 following discontinuation of several oral opioid products (e.g. hydromorphone).12
2024	Restriction of vapes to therapeutic use Government policy response to address rising child and adolescent use of unregulated nicotine-containing vapes. Adult smokers seeking to use vaping as a cessation tool now use the SAS-C pathway.13

1989	Establishment of the SAS The SAS was established as part of the Therapeutic Goods Act to maintain access to essential medicines not listed on the ARTG, while maintaining public safety.1
2016	Legalisation of medicinal cannabis Decades of restricted research and patent difficulties reduced the commercial incentive to fund the large clinical trials needed for full TGA registration. The SAS has become the default pathway for medicinal cannabis submissions10 – particularly for chronic pain and anxiety – increasing almost 100-fold since 2018.11
2017	Introduction of SAS-C New access pathway introduced in response to TGA medical devices review.3
2021	Discontinuation of opioids used in palliative care SAS volumes increased between 2021 and 2023 following discontinuation of several oral opioid products (e.g. hydromorphone).12
2024	Restriction of vapes to therapeutic use Government policy response to address rising child and adolescent use of unregulated nicotine-containing vapes. Adult smokers seeking to use vaping as a cessation tool now use the SAS-C pathway.13

1989	Establishment of the SAS The SAS was established as part of the Therapeutic Goods Act to maintain access to essential medicines not listed on the ARTG, while maintaining public safety.1
2016	Legalisation of medicinal cannabis Decades of restricted research and patent difficulties reduced the commercial incentive to fund the large clinical trials needed for full TGA registration. The SAS has become the default pathway for medicinal cannabis submissions10 – particularly for chronic pain and anxiety – increasing almost 100-fold since 2018.11
2017	Introduction of SAS-C New access pathway introduced in response to TGA medical devices review.3
2021	Discontinuation of opioids used in palliative care SAS volumes increased between 2021 and 2023 following discontinuation of several oral opioid products (e.g. hydromorphone).12
2024	Restriction of vapes to therapeutic use Government policy response to address rising child and adolescent use of unregulated nicotine-containing vapes. Adult smokers seeking to use vaping as a cessation tool now use the SAS-C pathway.13

1989	Establishment of the SAS The SAS was established as part of the Therapeutic Goods Act to maintain access to essential medicines not listed on the ARTG, while maintaining public safety.1
2016	Legalisation of medicinal cannabis Decades of restricted research and patent difficulties reduced the commercial incentive to fund the large clinical trials needed for full TGA registration. The SAS has become the default pathway for medicinal cannabis submissions10 – particularly for chronic pain and anxiety – increasing almost 100-fold since 2018.11
2017	Introduction of SAS-C New access pathway introduced in response to TGA medical devices review.3
2021	Discontinuation of opioids used in palliative care SAS volumes increased between 2021 and 2023 following discontinuation of several oral opioid products (e.g. hydromorphone).12
2024	Restriction of vapes to therapeutic use Government policy response to address rising child and adolescent use of unregulated nicotine-containing vapes. Adult smokers seeking to use vaping as a cessation tool now use the SAS-C pathway.13

What has your career looked like so far?

Why aged care?

What are the challenges and rewards of working in this setting?

Tell us about the training program for onsite pharmacists you’re developing.

What are the next steps?

How could the ACOP program improve?

Who’s your audience?

Does placement matter?

Beyond the label

References

Regulatory obligations

Professional responsibilities

Lack of approved Product Information, CMI and clinical guidelines

Drug interactions

Entry in clinical software

Informed patient consent

Direct importation becomes sponsorship

Considering risks of treatment

The SAS timeline

References

1. Who can administer FluMist?

2. Can pharmacists co-administer vaccines?

3. Can pharmacists vaccinate interstate?

4. How do pharmacists maintain immunisation credentials?

A system under strain

One-stop medicinal cannabis shops

Profit over patients

Driving under the influence

Misleading marketing

A lack of evidence

What next?

References

What has your career looked like so far?

Why aged care?

What are the challenges and rewards of working in this setting?

Tell us about the training program for onsite pharmacists you’re developing.

What are the next steps?

How could the ACOP program improve?

Who’s your audience?

Does placement matter?

Beyond the label

References

Regulatory obligations

Professional responsibilities

Lack of approved Product Information, CMI and clinical guidelines

Drug interactions

Entry in clinical software

Informed patient consent

Direct importation becomes sponsorship

Considering risks of treatment

The SAS timeline

References

1. Who can administer FluMist?

2. Can pharmacists co-administer vaccines?

3. Can pharmacists vaccinate interstate?

4. How do pharmacists maintain immunisation credentials?

A system under strain

One-stop medicinal cannabis shops

Profit over patients

Driving under the influence

Misleading marketing

A lack of evidence

What next?

References

What has your career looked like so far?

Why aged care?

What are the challenges and rewards of working in this setting?

Tell us about the training program for onsite pharmacists you’re developing.

What are the next steps?

How could the ACOP program improve?

Who’s your audience?

Does placement matter?

Beyond the label

References

Regulatory obligations

Professional responsibilities

Lack of approved Product Information, CMI and clinical guidelines

Drug interactions

Entry in clinical software

Informed patient consent